-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, major listed pharmaceutical companies have intensively disclosed their 2021 performance forecasts.
According to the author's incomplete statistics, more than 50 pharmaceutical companies released annual performance forecasts on January 29 alone.
Overall, there are mixed results
.
More than 50 pharmaceutical companies have disclosed their 2021 performance forecasts, and 7 companies are expected to double their net profits (Source: Pharmaceutical Network) , CanSino, Junshi Bio, Guangzheng Ophthalmology, Innovative Medical, TusHoldings Pharmaceuticals, Yihua Health and many other pharmaceutical companies are expected to have positive results in 2021
.
Among them, 7 companies are expected to double their net profit, namely Harbin Sanlian, Palin Bio, Northeast Pharmaceutical, Xinhua Medical, Tasly, Haili Bio, and Jiudian Pharmaceutical
.
Specifically, the 2021 annual report performance forecast released by Harbin Sanlian shows that the company’s net profit is expected to increase by 1090.
12% to 1192.
42%; Northeast Pharmaceuticals expects a net profit growth rate of 552.
70% to 879.
05% last year; Haili Bio’s expected net profit growth rate 493.
73% to 605.
75%
.
In addition, Jiudian Pharmaceutical, Pyrin Bio, Xinhua Medical, Tasly, etc.
are expected to increase their net profit by more than 100% in 2021
.
From the perspective of the reasons for the growth in performance, it is mainly related to the active strategies adopted by the relevant companies, refined management, and overseas export growth
.
For example, Perrin pointed out in the report that the company firmly implements the "three-step" strategic plan, emphasizing both endogenous and extension, the effect of extension expansion is evident, the supply of raw plasma has increased significantly, the variety of products has increased year-on-year, and the product structure has been continuously optimized.
The sales strategy has achieved both volume and price increases.
In addition, overseas exports have achieved a big breakthrough and the trend is improving, and the sales profit has increased significantly year-on-year
.
During the reporting period, Northeast Pharmaceuticals actively carried out sales business, formulated differentiated marketing strategies, and effectively enhanced product competitiveness; at the same time, the company continued to strengthen corporate management, using various measures such as structural adjustment, technological breakthroughs, process optimization, cost reduction and efficiency improvement, etc.
, quantify the refined management to each position, so that the benefits are fully reflected in all links of supply, production and sales, and promote the company's net profit after deducting non-recurring gains and losses to achieve substantial growth
.
During the reporting period, Xinhua Medical implemented the work guideline of "adjusting the structure, strengthening the main business, improving efficiency and preventing risks" and the general tone of high-quality development, focusing on the main business, concentrating superior resources and focusing on the development of manufacturing products in medical devices, pharmaceutical equipment and other sectors , continue to carry out in-depth quality and efficiency improvement, optimize the company's product structure, improve the gross profit rate, and improve the company's profitability
.
During the reporting period, Jiudian Pharmaceutical closely followed the national pharmaceutical policy reform trends, and on the basis of fully grasping market information, combined with the company's competitive advantages, formulated targeted marketing strategies, continuously opened up the market, and cultivated the field of high-end transdermal patches Products, main business income and net profit have achieved high growth
.
Of course, some people are happy and some are sad.
Judging from the list of pre-reduced performance, they include Zejing Pharmaceutical, Seli Medical, Tailong Pharmaceutical, Watson Bio, China Pharmaceutical, Guangyuyuan, Lukang Pharmaceutical, Huahai Pharmaceutical, Nanning New Pharmaceutical, Shengda Bio, Zhende Medical, Dali Pharmaceutical, Frontier Bio, Shenzhou Cell, Sino Medical, Aidi Pharmaceutical, Wisdom Medicine, Steady Medical, Wanchen Bio, Sialon Pharmaceutical, Lamei Pharmaceutical, Ogilvy Medical, Dongcheng Pharmaceutical, Shangrong Medical, Yuheng Pharmaceutical, Lanfan Medical, Asia Pacific Pharmaceutical, Haixiang Pharmaceutical, Meinian Health, Yifan Pharmaceutical, Jingfeng Pharmaceutical, Hainan Haiyao, Sihuan Bio , ST Chinese Medicine, Nanhua Biological,
etc.
Among them, Sino Medical's net profit in 2021 is expected to decline by 722.
5% to 682.
48%, Smart Medicine is expected to decline by 478% to 355%, Sihuan Biotechnology is expected to decline by 341.
8% to 220.
9%, and Nanhua Biotechnology is expected to decline by 302.
34% To 265.
55%, Aidi Pharmaceuticals fell from 182.
97% to 155.
32%
.
According to the author's incomplete statistics, more than 50 pharmaceutical companies released annual performance forecasts on January 29 alone.
Overall, there are mixed results
.
More than 50 pharmaceutical companies have disclosed their 2021 performance forecasts, and 7 companies are expected to double their net profits (Source: Pharmaceutical Network) , CanSino, Junshi Bio, Guangzheng Ophthalmology, Innovative Medical, TusHoldings Pharmaceuticals, Yihua Health and many other pharmaceutical companies are expected to have positive results in 2021
.
Among them, 7 companies are expected to double their net profit, namely Harbin Sanlian, Palin Bio, Northeast Pharmaceutical, Xinhua Medical, Tasly, Haili Bio, and Jiudian Pharmaceutical
.
Specifically, the 2021 annual report performance forecast released by Harbin Sanlian shows that the company’s net profit is expected to increase by 1090.
12% to 1192.
42%; Northeast Pharmaceuticals expects a net profit growth rate of 552.
70% to 879.
05% last year; Haili Bio’s expected net profit growth rate 493.
73% to 605.
75%
.
In addition, Jiudian Pharmaceutical, Pyrin Bio, Xinhua Medical, Tasly, etc.
are expected to increase their net profit by more than 100% in 2021
.
From the perspective of the reasons for the growth in performance, it is mainly related to the active strategies adopted by the relevant companies, refined management, and overseas export growth
.
For example, Perrin pointed out in the report that the company firmly implements the "three-step" strategic plan, emphasizing both endogenous and extension, the effect of extension expansion is evident, the supply of raw plasma has increased significantly, the variety of products has increased year-on-year, and the product structure has been continuously optimized.
The sales strategy has achieved both volume and price increases.
In addition, overseas exports have achieved a big breakthrough and the trend is improving, and the sales profit has increased significantly year-on-year
.
During the reporting period, Northeast Pharmaceuticals actively carried out sales business, formulated differentiated marketing strategies, and effectively enhanced product competitiveness; at the same time, the company continued to strengthen corporate management, using various measures such as structural adjustment, technological breakthroughs, process optimization, cost reduction and efficiency improvement, etc.
, quantify the refined management to each position, so that the benefits are fully reflected in all links of supply, production and sales, and promote the company's net profit after deducting non-recurring gains and losses to achieve substantial growth
.
During the reporting period, Xinhua Medical implemented the work guideline of "adjusting the structure, strengthening the main business, improving efficiency and preventing risks" and the general tone of high-quality development, focusing on the main business, concentrating superior resources and focusing on the development of manufacturing products in medical devices, pharmaceutical equipment and other sectors , continue to carry out in-depth quality and efficiency improvement, optimize the company's product structure, improve the gross profit rate, and improve the company's profitability
.
During the reporting period, Jiudian Pharmaceutical closely followed the national pharmaceutical policy reform trends, and on the basis of fully grasping market information, combined with the company's competitive advantages, formulated targeted marketing strategies, continuously opened up the market, and cultivated the field of high-end transdermal patches Products, main business income and net profit have achieved high growth
.
Of course, some people are happy and some are sad.
Judging from the list of pre-reduced performance, they include Zejing Pharmaceutical, Seli Medical, Tailong Pharmaceutical, Watson Bio, China Pharmaceutical, Guangyuyuan, Lukang Pharmaceutical, Huahai Pharmaceutical, Nanning New Pharmaceutical, Shengda Bio, Zhende Medical, Dali Pharmaceutical, Frontier Bio, Shenzhou Cell, Sino Medical, Aidi Pharmaceutical, Wisdom Medicine, Steady Medical, Wanchen Bio, Sialon Pharmaceutical, Lamei Pharmaceutical, Ogilvy Medical, Dongcheng Pharmaceutical, Shangrong Medical, Yuheng Pharmaceutical, Lanfan Medical, Asia Pacific Pharmaceutical, Haixiang Pharmaceutical, Meinian Health, Yifan Pharmaceutical, Jingfeng Pharmaceutical, Hainan Haiyao, Sihuan Bio , ST Chinese Medicine, Nanhua Biological,
etc.
Among them, Sino Medical's net profit in 2021 is expected to decline by 722.
5% to 682.
48%, Smart Medicine is expected to decline by 478% to 355%, Sihuan Biotechnology is expected to decline by 341.
8% to 220.
9%, and Nanhua Biotechnology is expected to decline by 302.
34% To 265.
55%, Aidi Pharmaceuticals fell from 182.
97% to 155.
32%
.
